Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
| DrugCom Name |
DrugCom ID |
Component Drug |
Indication |
REF |
|
ABIRATERONE + Vemurafenib
|
DC9DLT6
|
ABIRATERONE
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
ABIRATERONE + Vemurafenib
|
DCCCAT7
|
ABIRATERONE
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
ABIRATERONE + Vemurafenib
|
DCOE67G
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
ABIRATERONE + Vemurafenib
|
DCJ31D6
|
ABIRATERONE
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
ABIRATERONE + Vemurafenib
|
DCZNZ5H
|
ABIRATERONE
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
ABIRATERONE + Vemurafenib
|
DCK5BVU
|
ABIRATERONE
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
ABIRATERONE + Vemurafenib
|
DCBK5JJ
|
ABIRATERONE
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Amonafide + Vemurafenib
|
DCEFFUJ
|
Amonafide
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
Anastrozole + Vemurafenib
|
DCAZE9H
|
Anastrozole
|
Adenocarcinoma (Cell Line: DU-145)
|
[2] |
|
Anastrozole + Vemurafenib
|
DCXR3GH
|
Anastrozole
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[2] |
|
Anastrozole + Vemurafenib
|
DCTNCL2
|
Anastrozole
|
Adenocarcinoma (Cell Line: A549)
|
[2] |
|
Anastrozole + Vemurafenib
|
DCROAA3
|
Anastrozole
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Anastrozole + Vemurafenib
|
DC69RB4
|
Anastrozole
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Anastrozole + Vemurafenib
|
DCMIKP6
|
Anastrozole
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[2] |
|
Anastrozole + Vemurafenib
|
DCNI8BE
|
Anastrozole
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[2] |
|
Arfolitixorin + Vemurafenib
|
DCULCVT
|
Arfolitixorin
|
Glioma (Cell Line: SF-295)
|
[2] |
|
Arfolitixorin + Vemurafenib
|
DC02Y2S
|
Arfolitixorin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Arfolitixorin + Vemurafenib
|
DCLKCPE
|
Arfolitixorin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Cabazitaxel + Vemurafenib
|
DC9AQM3
|
Cabazitaxel
|
Amelanotic melanoma (Cell Line: M14)
|
[2] |
|
Cabazitaxel + Vemurafenib
|
DCV59G5
|
Cabazitaxel
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Cabazitaxel + Vemurafenib
|
DC4F363
|
Cabazitaxel
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
Cabazitaxel + Vemurafenib
|
DC7T4IF
|
Cabazitaxel
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[2] |
|
Cabazitaxel + Vemurafenib
|
DC4PG0D
|
Cabazitaxel
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[2] |
|
Cabazitaxel + Vemurafenib
|
DC8KBM5
|
Cabazitaxel
|
Melanoma (Cell Line: MALME-3M)
|
[2] |
|
Cabazitaxel + Vemurafenib
|
DCSZOBO
|
Cabazitaxel
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[2] |
|
Cabazitaxel + Vemurafenib
|
DCHWQ8Q
|
Cabazitaxel
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
Crizotinib + Vemurafenib
|
DCMCEI9
|
Crizotinib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[2] |
|
Crizotinib + Vemurafenib
|
DCBJOQY
|
Crizotinib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Crizotinib + Vemurafenib
|
DCDINB7
|
Crizotinib
|
Malignant melanoma (Cell Line: UACC62)
|
[2] |
|
Crizotinib + Vemurafenib
|
DCI8CIP
|
Crizotinib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[2] |
|
Crizotinib + Vemurafenib
|
DCDAYMD
|
Crizotinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Dacarbazine + Vemurafenib
|
DCMBBNW
|
Dacarbazine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[2] |
|
Dacarbazine + Vemurafenib
|
DCYGKN6
|
Dacarbazine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Dacarbazine + Vemurafenib
|
DC2LEYC
|
Dacarbazine
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Dacarbazine + Vemurafenib
|
DCOSCZA
|
Dacarbazine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Dacarbazine + Vemurafenib
|
DCW0J9I
|
Dacarbazine
|
Glioma (Cell Line: SF-295)
|
[2] |
|
Dacarbazine + Vemurafenib
|
DCN2DJ3
|
Dacarbazine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[2] |
|
Dacarbazine + Vemurafenib
|
DCGKNBB
|
Dacarbazine
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[2] |
|
Dexrazoxane + Vemurafenib
|
DCEJAV2
|
Dexrazoxane
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Dexrazoxane + Vemurafenib
|
DC5YFHX
|
Dexrazoxane
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Dexrazoxane + Vemurafenib
|
DCJVUY4
|
Dexrazoxane
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Epirubicin + Vemurafenib
|
DCFVGR5
|
Epirubicin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Epirubicin + Vemurafenib
|
DCY21CB
|
Epirubicin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Epirubicin + Vemurafenib
|
DCV1ZVB
|
Epirubicin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Epirubicin + Vemurafenib
|
DCLIIXU
|
Epirubicin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Epirubicin + Vemurafenib
|
DC5XQX3
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
Epirubicin + Vemurafenib
|
DCMDNSH
|
Epirubicin
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
Epirubicin + Vemurafenib
|
DC3I2P9
|
Epirubicin
|
Glioma (Cell Line: SF-539)
|
[2] |
|
Epirubicin + Vemurafenib
|
DCMLO4I
|
Epirubicin
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Epirubicin + Vemurafenib
|
DC23Y76
|
Epirubicin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
Epirubicin + Vemurafenib
|
DCNB1E1
|
Epirubicin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Epirubicin + Vemurafenib
|
DC16W88
|
Epirubicin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
Epirubicin + Vemurafenib
|
DCE6CTN
|
Epirubicin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Epirubicin + Vemurafenib
|
DC84ZWP
|
Epirubicin
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Epirubicin + Vemurafenib
|
DC1J7S5
|
Epirubicin
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Epirubicin + Vemurafenib
|
DCGQ9FN
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Epirubicin + Vemurafenib
|
DCZO7BY
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Epirubicin + Vemurafenib
|
DC1UDPO
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Epirubicin + Vemurafenib
|
DCNF5AN
|
Epirubicin
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Epirubicin + Vemurafenib
|
DCKGOTS
|
Epirubicin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Epirubicin + Vemurafenib
|
DC0GSVV
|
Epirubicin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Epirubicin + Vemurafenib
|
DCUYKWT
|
Epirubicin
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Epirubicin + Vemurafenib
|
DCGK8GQ
|
Epirubicin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Epirubicin + Vemurafenib
|
DCZ70G5
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Epirubicin + Vemurafenib
|
DC292NL
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Epirubicin + Vemurafenib
|
DC6HE7H
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Epirubicin + Vemurafenib
|
DCXJOGL
|
Epirubicin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Epirubicin + Vemurafenib
|
DCM88G8
|
Epirubicin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Epirubicin + Vemurafenib
|
DCMRG5B
|
Epirubicin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Epirubicin + Vemurafenib
|
DCWVMLO
|
Epirubicin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Epirubicin + Vemurafenib
|
DCMLCJE
|
Epirubicin
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Epirubicin + Vemurafenib
|
DCQDCZ6
|
Epirubicin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Epirubicin + Vemurafenib
|
DC65UAX
|
Epirubicin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Epirubicin + Vemurafenib
|
DCNT563
|
Epirubicin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Epirubicin + Vemurafenib
|
DC5DQQI
|
Epirubicin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Epirubicin + Vemurafenib
|
DCFUFG3
|
Epirubicin
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Gefitinib + Vemurafenib
|
DCY7823
|
Gefitinib
|
Adenocarcinoma (Cell Line: HT29)
|
[2] |
|
Gefitinib + Vemurafenib
|
DCRYU44
|
Gefitinib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Gefitinib + Vemurafenib
|
DCSXXIN
|
Gefitinib
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[2] |
|
Gefitinib + Vemurafenib
|
DCVVTAP
|
Gefitinib
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Gefitinib + Vemurafenib
|
DCIKFQH
|
Gefitinib
|
Melanoma (Cell Line: MALME-3M)
|
[2] |
|
Indazole derivative 5 + Vemurafenib
|
DCVP7FR
|
Indazole derivative 5
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Indazole derivative 5 + Vemurafenib
|
DCE6L26
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Indazole derivative 5 + Vemurafenib
|
DCS9WPC
|
Indazole derivative 5
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Vemurafenib
|
DCR38V3
|
Indazole derivative 5
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
JNK-IN-8 + Vemurafenib
|
DCPGDSI
|
JNK-IN-8
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
JNK-IN-8 + Vemurafenib
|
DC9IN8M
|
JNK-IN-8
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Lenalidomide + Vemurafenib
|
DC0SHW0
|
Lenalidomide
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Lenalidomide + Vemurafenib
|
DC41NZB
|
Lenalidomide
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Mechlorethamine + Vemurafenib
|
DCV5ZB4
|
Mechlorethamine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Mechlorethamine + Vemurafenib
|
DCT3Z0O
|
Mechlorethamine
|
Glioma (Cell Line: SF-295)
|
[2] |
|
Mechlorethamine + Vemurafenib
|
DC4H4OE
|
Mechlorethamine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Mechlorethamine + Vemurafenib
|
DCWF584
|
Mechlorethamine
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
Mechlorethamine + Vemurafenib
|
DCFD93E
|
Mechlorethamine
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Mechlorethamine + Vemurafenib
|
DCCU4ZE
|
Mechlorethamine
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Mechlorethamine + Vemurafenib
|
DCPMI2S
|
Mechlorethamine
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Mechlorethamine + Vemurafenib
|
DCSNA4K
|
Mechlorethamine
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Mechlorethamine + Vemurafenib
|
DCW3LT4
|
Mechlorethamine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Mechlorethamine + Vemurafenib
|
DCWXGMJ
|
Mechlorethamine
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Mechlorethamine + Vemurafenib
|
DCV4RGA
|
Mechlorethamine
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Mechlorethamine + Vemurafenib
|
DC1DGAI
|
Mechlorethamine
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Picoplatin + Vemurafenib
|
DCD0EN1
|
Picoplatin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Picoplatin + Vemurafenib
|
DCVJRQD
|
Picoplatin
|
Glioma (Cell Line: SF-295)
|
[2] |
|
Picoplatin + Vemurafenib
|
DC1OUAV
|
Picoplatin
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Picoplatin + Vemurafenib
|
DCZPBLW
|
Picoplatin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
Picoplatin + Vemurafenib
|
DCQSXAM
|
Picoplatin
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Picoplatin + Vemurafenib
|
DCX4UTX
|
Picoplatin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Picoplatin + Vemurafenib
|
DC16W9R
|
Picoplatin
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Picoplatin + Vemurafenib
|
DCR423I
|
Picoplatin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Picoplatin + Vemurafenib
|
DCAEBFF
|
Picoplatin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Picoplatin + Vemurafenib
|
DCHRUWV
|
Picoplatin
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Raloxifene + Vemurafenib
|
DC5AZDU
|
Raloxifene
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Raloxifene + Vemurafenib
|
DC11K7H
|
Raloxifene
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Raloxifene + Vemurafenib
|
DC5CH2C
|
Raloxifene
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Raloxifene + Vemurafenib
|
DCSGGQ3
|
Raloxifene
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
Raloxifene + Vemurafenib
|
DCBDJ6J
|
Raloxifene
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Raloxifene + Vemurafenib
|
DCKDU9U
|
Raloxifene
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Raloxifene + Vemurafenib
|
DC1691S
|
Raloxifene
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Raloxifene + Vemurafenib
|
DC60Y8Z
|
Raloxifene
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Raloxifene + Vemurafenib
|
DCUKQIJ
|
Raloxifene
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Raloxifene + Vemurafenib
|
DC8NNYZ
|
Raloxifene
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Raloxifene + Vemurafenib
|
DCDV2YL
|
Raloxifene
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Raloxifene + Vemurafenib
|
DCHIHXU
|
Raloxifene
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Raloxifene + Vemurafenib
|
DCIXX9Q
|
Raloxifene
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Raloxifene + Vemurafenib
|
DCFW2DL
|
Raloxifene
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Raloxifene + Vemurafenib
|
DCQEVMU
|
Raloxifene
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Raloxifene + Vemurafenib
|
DCACDAU
|
Raloxifene
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Raloxifene + Vemurafenib
|
DCG5P4O
|
Raloxifene
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Raloxifene + Vemurafenib
|
DC9G6QX
|
Raloxifene
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Ruxolitinib + Vemurafenib
|
DCJ0OOS
|
Ruxolitinib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Ruxolitinib + Vemurafenib
|
DCZ3UEG
|
Ruxolitinib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Ruxolitinib + Vemurafenib
|
DCYFTCS
|
Ruxolitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Ruxolitinib + Vemurafenib
|
DCXGXQV
|
Ruxolitinib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Thioguanine + Vemurafenib
|
DCG4KXC
|
Thioguanine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Thioguanine + Vemurafenib
|
DCZ73D6
|
Thioguanine
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Thioguanine + Vemurafenib
|
DCJTOB8
|
Thioguanine
|
Glioma (Cell Line: SF-295)
|
[2] |
|
Thioguanine + Vemurafenib
|
DC3TE9T
|
Thioguanine
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Thioguanine + Vemurafenib
|
DC1VTR3
|
Thioguanine
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Thioguanine + Vemurafenib
|
DCCWJMX
|
Thioguanine
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Thioguanine + Vemurafenib
|
DC5OVOO
|
Thioguanine
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Thioguanine + Vemurafenib
|
DCDNH67
|
Thioguanine
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Thioguanine + Vemurafenib
|
DCHLB1H
|
Thioguanine
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Topotecan + Vemurafenib
|
DCH0I2C
|
Topotecan
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Topotecan + Vemurafenib
|
DCRKMG5
|
Topotecan
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Topotecan + Vemurafenib
|
DCLHUUJ
|
Topotecan
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Topotecan + Vemurafenib
|
DCO8824
|
Topotecan
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Topotecan + Vemurafenib
|
DC6X39I
|
Topotecan
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Topotecan + Vemurafenib
|
DCWNGKC
|
Topotecan
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Topotecan + Vemurafenib
|
DCIJ68L
|
Topotecan
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Topotecan + Vemurafenib
|
DCEWLT9
|
Topotecan
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Topotecan + Vemurafenib
|
DC0I5VV
|
Topotecan
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Topotecan + Vemurafenib
|
DCOOYO7
|
Topotecan
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Topotecan + Vemurafenib
|
DC70Q7F
|
Topotecan
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Trifluridine + Vemurafenib
|
DC4TN6I
|
Trifluridine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Trifluridine + Vemurafenib
|
DCH516M
|
Trifluridine
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Uracil mustard + Vemurafenib
|
DCY7QVY
|
Uracil mustard
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Uracil mustard + Vemurafenib
|
DCGJD01
|
Uracil mustard
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vandetanib + Vemurafenib
|
DCJSGYE
|
Vandetanib
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Vandetanib + Vemurafenib
|
DC8F3HR
|
Vandetanib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vandetanib + Vemurafenib
|
DC2UZ7X
|
Vandetanib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Vandetanib + Vemurafenib
|
DCQ119I
|
Vandetanib
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + Pentostatin
|
DCKBTCJ
|
Pentostatin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Vemurafenib + Pentostatin
|
DC5GTFG
|
Pentostatin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vemurafenib + Fulvestrant
|
DCUFP8H
|
Fulvestrant
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Vemurafenib + Fulvestrant
|
DCDU9UY
|
Fulvestrant
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + Fulvestrant
|
DCQNFH2
|
Fulvestrant
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vemurafenib + Gefitinib
|
DC2AACB
|
Gefitinib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vemurafenib + Gefitinib
|
DCJ67C0
|
Gefitinib
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Vemurafenib + Gefitinib
|
DCBQUSX
|
Gefitinib
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Vemurafenib + Gefitinib
|
DCUB1LX
|
Gefitinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + Gefitinib
|
DCO6NLJ
|
Gefitinib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vemurafenib + Gefitinib
|
DC6U1Y2
|
Gefitinib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Vemurafenib + Hepzato
|
DCM6EEB
|
Hepzato
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + Ixabepilone
|
DCL6636
|
Ixabepilone
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Vemurafenib + Dactinomycin
|
DC6WQSH
|
Dactinomycin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vemurafenib + Dactinomycin
|
DCJF6IN
|
Dactinomycin
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Vemurafenib + Dactinomycin
|
DC8D3U0
|
Dactinomycin
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Vemurafenib + Dactinomycin
|
DC2W0GH
|
Dactinomycin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Vemurafenib + Dactinomycin
|
DCOGS3X
|
Dactinomycin
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Vemurafenib + Dactinomycin
|
DCYYZEV
|
Dactinomycin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + Dactinomycin
|
DCI3XU9
|
Dactinomycin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vemurafenib + Dactinomycin
|
DCCQAKR
|
Dactinomycin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Vemurafenib + DFN-15
|
DC41RW6
|
DFN-15
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vemurafenib + DFN-15
|
DC199T7
|
DFN-15
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Vemurafenib + DFN-15
|
DCFDC2E
|
DFN-15
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vemurafenib + Lapatinib
|
DC27MQY
|
Lapatinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + PMID28460551-Compound-2
|
DCYHLFC
|
PMID28460551-Compound-2
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Vemurafenib + Cyclophosphamide
|
DC4NZOD
|
Cyclophosphamide
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Vemurafenib + Cyclophosphamide
|
DC3BO8Y
|
Cyclophosphamide
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Vemurafenib + Cyclophosphamide
|
DCCOLKH
|
Cyclophosphamide
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vemurafenib + Methotrexate
|
DC0ZUOC
|
Methotrexate
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Vemurafenib + Methotrexate
|
DC8B7IC
|
Methotrexate
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + Vismodegib
|
DC5T96N
|
Vismodegib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vemurafenib + Isoniazid
|
DC52GNO
|
Isoniazid
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Vemurafenib + Isoniazid
|
DCWEDQC
|
Isoniazid
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Vemurafenib + Isoniazid
|
DCYIF6I
|
Isoniazid
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vemurafenib + Arsenic trioxide
|
DCSZDO8
|
Arsenic trioxide
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Vemurafenib + Arsenic trioxide
|
DCCZZSN
|
Arsenic trioxide
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vemurafenib + Lenalidomide
|
DCJ5RLZ
|
Lenalidomide
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vemurafenib + Lenalidomide
|
DCYOFFV
|
Lenalidomide
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Vemurafenib + Plicamycin
|
DC05WSL
|
Plicamycin
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Vemurafenib + Plicamycin
|
DCWHHQN
|
Plicamycin
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Vemurafenib + Plicamycin
|
DCH9FDL
|
Plicamycin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Vemurafenib + Plicamycin
|
DCF9N8A
|
Plicamycin
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Vemurafenib + Plicamycin
|
DCX9W8B
|
Plicamycin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vemurafenib + Plicamycin
|
DCNLBE5
|
Plicamycin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Vemurafenib + Plicamycin
|
DCZTZ9E
|
Plicamycin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + Nilotinib
|
DCBYKDR
|
Nilotinib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vemurafenib + Nilotinib
|
DCTXLW3
|
Nilotinib
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Vemurafenib + Nilotinib
|
DCWLMIQ
|
Nilotinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + Thioguanine
|
DCQR9IC
|
Thioguanine
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vemurafenib + Thioguanine
|
DCW8OW1
|
Thioguanine
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Vemurafenib + Thioguanine
|
DC5UC31
|
Thioguanine
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Vemurafenib + Thioguanine
|
DCANGXD
|
Thioguanine
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Vemurafenib + Thioguanine
|
DCJZS8T
|
Thioguanine
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vemurafenib + Thioguanine
|
DCYSPML
|
Thioguanine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + Thioguanine
|
DCNPQSN
|
Thioguanine
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Vemurafenib + ABIRATERONE
|
DCWQ0R0
|
ABIRATERONE
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vemurafenib + 10-hydroxycamptothecin
|
DCDBSN5
|
10-hydroxycamptothecin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Vemurafenib + 10-hydroxycamptothecin
|
DCAV4PF
|
10-hydroxycamptothecin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + Amonafide
|
DCCYNHW
|
Amonafide
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Vemurafenib + Pralatrexate
|
DC2OBHX
|
Pralatrexate
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Vemurafenib + Pralatrexate
|
DCF6MI1
|
Pralatrexate
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Vemurafenib + Pralatrexate
|
DCTWYIE
|
Pralatrexate
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + Terameprocol
|
DC6RUMA
|
Terameprocol
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Vemurafenib + Terameprocol
|
DC6Y6IU
|
Terameprocol
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Vemurafenib + Terameprocol
|
DCY6P8D
|
Terameprocol
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Vemurafenib + Terameprocol
|
DCX50SK
|
Terameprocol
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vemurafenib + SCH 727965
|
DCSL93U
|
SCH 727965
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vemurafenib + SCH 727965
|
DCUHWNK
|
SCH 727965
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Vemurafenib + SCH 727965
|
DCNPUVY
|
SCH 727965
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + Dexrazoxane
|
DCAY238
|
Dexrazoxane
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vemurafenib + Dexrazoxane
|
DCJNVWT
|
Dexrazoxane
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Vemurafenib + Dexrazoxane
|
DCZN75E
|
Dexrazoxane
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Vemurafenib + Docetaxel
|
DCVGNLV
|
Docetaxel
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vemurafenib + Docetaxel
|
DCFNP6S
|
Docetaxel
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Vemurafenib + Docetaxel
|
DCW1E81
|
Docetaxel
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Vemurafenib + Raloxifene
|
DCNY104
|
Raloxifene
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vemurafenib + Raloxifene
|
DCOMO3U
|
Raloxifene
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Vemurafenib + Raloxifene
|
DC8II47
|
Raloxifene
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Vemurafenib + Raloxifene
|
DCIZAED
|
Raloxifene
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vemurafenib + Raloxifene
|
DCVO64L
|
Raloxifene
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + Bendamustine hydrochloride
|
DCRFXZX
|
Bendamustine hydrochloride
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vemurafenib + Bendamustine hydrochloride
|
DCQ0BEV
|
Bendamustine hydrochloride
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vemurafenib + Trifluridine
|
DCHC0IA
|
Trifluridine
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Vemurafenib + Trifluridine
|
DCYXC1L
|
Trifluridine
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vemurafenib + Trifluridine
|
DC7J3AC
|
Trifluridine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + Sirolimus
|
DC3GK5T
|
Sirolimus
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vemurafenib + Sirolimus
|
DC4EIN7
|
Sirolimus
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Vemurafenib + Sirolimus
|
DCIUX4O
|
Sirolimus
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Vemurafenib + Sirolimus
|
DCX6ZOG
|
Sirolimus
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Vemurafenib + Sirolimus
|
DCCKC4S
|
Sirolimus
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + Sirolimus
|
DC3FEP3
|
Sirolimus
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Vemurafenib + Letrozole
|
DC33Y34
|
Letrozole
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vemurafenib + Letrozole
|
DCWXLV5
|
Letrozole
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Vemurafenib + Letrozole
|
DCB5K45
|
Letrozole
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vemurafenib + Letrozole
|
DCKBSC9
|
Letrozole
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Vemurafenib + Mitomycin
|
DCX0QTD
|
Mitomycin
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Vemurafenib + Mitomycin
|
DCZRVZ3
|
Mitomycin
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Vemurafenib + Mitomycin
|
DC1L4QK
|
Mitomycin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Vemurafenib + Mitomycin
|
DCQV4Z3
|
Mitomycin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vemurafenib + Uracil mustard
|
DCTCS7T
|
Uracil mustard
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vemurafenib + Uracil mustard
|
DCMJWFP
|
Uracil mustard
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Vemurafenib + Uracil mustard
|
DC6G37U
|
Uracil mustard
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Vemurafenib + Uracil mustard
|
DCXXYJ1
|
Uracil mustard
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + Vincristine
|
DCKABA1
|
Vincristine
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vemurafenib + Arfolitixorin
|
DCSRMP7
|
Arfolitixorin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vemurafenib + Arfolitixorin
|
DCMUG3U
|
Arfolitixorin
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Vemurafenib + Arfolitixorin
|
DC14OG4
|
Arfolitixorin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Vemurafenib + Arfolitixorin
|
DCKTQTB
|
Arfolitixorin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Vemurafenib + BIO-300
|
DCAL3G9
|
BIO-300
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vemurafenib + BIO-300
|
DCSDRSI
|
BIO-300
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Vemurafenib + BIO-300
|
DC5Y4GA
|
BIO-300
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Vemurafenib + BIO-300
|
DCHRESK
|
BIO-300
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Vemurafenib + BIO-300
|
DCHAMDM
|
BIO-300
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + TEM
|
DCMU2P2
|
TEM
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vemurafenib + TEM
|
DCA74QS
|
TEM
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Vemurafenib + JNK-IN-8
|
DCFUZDP
|
JNK-IN-8
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vemurafenib + Idarubicin
|
DCXR7F8
|
Idarubicin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Vemurafenib + Indazole derivative 5
|
DCCP0TS
|
Indazole derivative 5
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vemurafenib + Indazole derivative 5
|
DCAVL9N
|
Indazole derivative 5
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + Imatinib
|
DCYGAS3
|
Imatinib
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Vemurafenib + Imatinib
|
DC29RC5
|
Imatinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + Bleomycin
|
DCM93CZ
|
Bleomycin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vemurafenib + Bleomycin
|
DCH06OI
|
Bleomycin
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Vemurafenib + Bleomycin
|
DCJ4F9G
|
Bleomycin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + Bortezomib
|
DCJY4UD
|
Bortezomib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vemurafenib + Bortezomib
|
DCJ82I9
|
Bortezomib
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Vemurafenib + Bortezomib
|
DCXDE73
|
Bortezomib
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Vemurafenib + Bortezomib
|
DCJT2HF
|
Bortezomib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Vemurafenib + Bortezomib
|
DCHN6WG
|
Bortezomib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + Anastrozole
|
DCLTIER
|
Anastrozole
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Vemurafenib + Dacarbazine
|
DCR89Q5
|
Dacarbazine
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vemurafenib + Dacarbazine
|
DCM1TTK
|
Dacarbazine
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Vemurafenib + Dacarbazine
|
DC0A2KM
|
Dacarbazine
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Vemurafenib + Dacarbazine
|
DC7IVWS
|
Dacarbazine
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vemurafenib + Dacarbazine
|
DCQNMCX
|
Dacarbazine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + Dacarbazine
|
DCT7CY8
|
Dacarbazine
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Vemurafenib + Valrubicin
|
DC357L4
|
Valrubicin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vemurafenib + Valrubicin
|
DC9DTJU
|
Valrubicin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Vemurafenib + Valrubicin
|
DC1MEII
|
Valrubicin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + Valrubicin
|
DC9PF3Y
|
Valrubicin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vemurafenib + Valrubicin
|
DC39B6D
|
Valrubicin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Vemurafenib + Topotecan
|
DCXQC1R
|
Topotecan
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vemurafenib + Topotecan
|
DCTLIVH
|
Topotecan
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Vemurafenib + Topotecan
|
DCK8IAJ
|
Topotecan
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Vemurafenib + Topotecan
|
DCOISCH
|
Topotecan
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Vemurafenib + Cabazitaxel
|
DCYVVUJ
|
Cabazitaxel
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Vemurafenib + Cabazitaxel
|
DCUTPGE
|
Cabazitaxel
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + Epirubicin
|
DCU854C
|
Epirubicin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vemurafenib + Epirubicin
|
DCB5JAJ
|
Epirubicin
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Vemurafenib + Epirubicin
|
DC7O15X
|
Epirubicin
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Vemurafenib + Epirubicin
|
DCIEB7D
|
Epirubicin
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Vemurafenib + Epirubicin
|
DC7EGAS
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Vemurafenib + Epirubicin
|
DCFAV03
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vemurafenib + Epirubicin
|
DCNH9RJ
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + Cisplatin
|
DCW0AHL
|
Cisplatin
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Vemurafenib + Cisplatin
|
DCO25DO
|
Cisplatin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + Vandetanib
|
DC3MIC9
|
Vandetanib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vemurafenib + ER819762
|
DCHOE5H
|
ER819762
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Vemurafenib + Azacitidine
|
DC9L0UQ
|
Azacitidine
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Vemurafenib + Azacitidine
|
DCN84QZ
|
Azacitidine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DCDBP0B
|
Pomalidomide
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DCVCX4I
|
Pomalidomide
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DCZSQYQ
|
Pomalidomide
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DCI4BRB
|
Pomalidomide
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vemurafenib + Mercaptopurine
|
DCNWZ09
|
Mercaptopurine
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Vemurafenib + Taxol
|
DCPWE9V
|
Taxol
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Vemurafenib + Fludarabine
|
DCDD3N5
|
Fludarabine
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Vemurafenib + PMID28870136-Compound-43
|
DCEW6UB
|
PMID28870136-Compound-43
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Vemurafenib + FORMESTANE
|
DCIIUNJ
|
FORMESTANE
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vemurafenib + FORMESTANE
|
DCW842T
|
FORMESTANE
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Vemurafenib + Estramustine
|
DCI5PVZ
|
Estramustine
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vemurafenib + Estramustine
|
DCIJMK0
|
Estramustine
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Vemurafenib + Estramustine
|
DCUPXGC
|
Estramustine
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vemurafenib + Digitoxin
|
DCJCFJA
|
Digitoxin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Vemurafenib + Mechlorethamine
|
DCVDNVK
|
Mechlorethamine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Vemurafenib + Mechlorethamine
|
DCFTERU
|
Mechlorethamine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Vemurafenib + Mechlorethamine
|
DCEJWH5
|
Mechlorethamine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Vemurafenib + Mechlorethamine
|
DCVYL0Y
|
Mechlorethamine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Vemurafenib + Mechlorethamine
|
DC6992A
|
Mechlorethamine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + Mechlorethamine
|
DCEPRNE
|
Mechlorethamine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Mechlorethamine
|
DCATCNW
|
Mechlorethamine
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Vemurafenib + Pentostatin
|
DCK50IU
|
Pentostatin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Vemurafenib + Pentostatin
|
DC6H2BG
|
Pentostatin
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Vemurafenib + Pentostatin
|
DCM8DEE
|
Pentostatin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
Vemurafenib + Pentostatin
|
DCXO75Y
|
Pentostatin
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Vemurafenib + Pentostatin
|
DCLW2DD
|
Pentostatin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Vemurafenib + Pentostatin
|
DCV6ASP
|
Pentostatin
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + Pentostatin
|
DC4PXB7
|
Pentostatin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Pentostatin
|
DCL5P1H
|
Pentostatin
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Vemurafenib + Picoplatin
|
DC8GDBR
|
Picoplatin
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Vemurafenib + Picoplatin
|
DC8NCOE
|
Picoplatin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Vemurafenib + Picoplatin
|
DCQOBZ2
|
Picoplatin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vemurafenib + Fulvestrant
|
DCYNGH2
|
Fulvestrant
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Vemurafenib + Fulvestrant
|
DCI23PE
|
Fulvestrant
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vemurafenib + Fulvestrant
|
DCNK460
|
Fulvestrant
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Vemurafenib + Fulvestrant
|
DCIUKMQ
|
Fulvestrant
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Vemurafenib + Fulvestrant
|
DCWCHQI
|
Fulvestrant
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
Vemurafenib + Fulvestrant
|
DCGYL45
|
Fulvestrant
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + Fulvestrant
|
DCCMG0L
|
Fulvestrant
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Vemurafenib + Fulvestrant
|
DC8N57J
|
Fulvestrant
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Vemurafenib + Fulvestrant
|
DCOG6IX
|
Fulvestrant
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Vemurafenib + Fulvestrant
|
DCHTUK6
|
Fulvestrant
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Vemurafenib + Fulvestrant
|
DCPSFC2
|
Fulvestrant
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vemurafenib + Fulvestrant
|
DC841VL
|
Fulvestrant
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + Fulvestrant
|
DCSJ8CY
|
Fulvestrant
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Vemurafenib + Fulvestrant
|
DCA0SWB
|
Fulvestrant
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vemurafenib + Fulvestrant
|
DCL3TPN
|
Fulvestrant
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Fulvestrant
|
DCOPDNR
|
Fulvestrant
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Vemurafenib + Gefitinib
|
DCIK7PU
|
Gefitinib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Vemurafenib + Gefitinib
|
DCCN7H0
|
Gefitinib
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Vemurafenib + Gefitinib
|
DCUJ0WT
|
Gefitinib
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vemurafenib + Gefitinib
|
DC8WHM2
|
Gefitinib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Vemurafenib + Gefitinib
|
DC4GFVV
|
Gefitinib
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Vemurafenib + Gefitinib
|
DCXE13I
|
Gefitinib
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Vemurafenib + Gefitinib
|
DCRNDE8
|
Gefitinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Vemurafenib + Gefitinib
|
DC6UQFQ
|
Gefitinib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Vemurafenib + Gefitinib
|
DCMSG5K
|
Gefitinib
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
Vemurafenib + Gefitinib
|
DCS8TX6
|
Gefitinib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + Gefitinib
|
DCVPJH8
|
Gefitinib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Gefitinib
|
DCM9AA0
|
Gefitinib
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Vemurafenib + Gefitinib
|
DCJ2QV9
|
Gefitinib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Vemurafenib + Gefitinib
|
DCR45OA
|
Gefitinib
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Vemurafenib + Gefitinib
|
DCBUHGK
|
Gefitinib
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Vemurafenib + Gefitinib
|
DCHL0S4
|
Gefitinib
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Vemurafenib + Gefitinib
|
DCG3YU7
|
Gefitinib
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Vemurafenib + Gefitinib
|
DCTCARF
|
Gefitinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Vemurafenib + Gefitinib
|
DCC43NM
|
Gefitinib
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vemurafenib + Gefitinib
|
DCNJNUN
|
Gefitinib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + Gefitinib
|
DCEFFFB
|
Gefitinib
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Gefitinib
|
DCSAG88
|
Gefitinib
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vemurafenib + Gefitinib
|
DCDJ46P
|
Gefitinib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Vemurafenib + Gefitinib
|
DC8BXUS
|
Gefitinib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vemurafenib + Gefitinib
|
DCQZ48G
|
Gefitinib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vemurafenib + Gefitinib
|
DCT6D29
|
Gefitinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Gefitinib
|
DCBK2SN
|
Gefitinib
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Vemurafenib + Gefitinib
|
DCCE4JW
|
Gefitinib
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Vemurafenib + Ruxolitinib
|
DC0TMPZ
|
Ruxolitinib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Vemurafenib + Ruxolitinib
|
DCJBFTN
|
Ruxolitinib
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Vemurafenib + Ruxolitinib
|
DCSDO7V
|
Ruxolitinib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Vemurafenib + Ruxolitinib
|
DCEH8YY
|
Ruxolitinib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Vemurafenib + Ruxolitinib
|
DCR87HO
|
Ruxolitinib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Ruxolitinib
|
DCTOM4D
|
Ruxolitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Vemurafenib + Ruxolitinib
|
DC0K09C
|
Ruxolitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Vemurafenib + Ruxolitinib
|
DCJAS3S
|
Ruxolitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Vemurafenib + Ruxolitinib
|
DCVNXSH
|
Ruxolitinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Vemurafenib + Ruxolitinib
|
DCEASGV
|
Ruxolitinib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Vemurafenib + Ruxolitinib
|
DCJG9MQ
|
Ruxolitinib
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + Hepzato
|
DC5MKEP
|
Hepzato
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Vemurafenib + Hepzato
|
DCL49VC
|
Hepzato
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Vemurafenib + Hepzato
|
DCJ4QEG
|
Hepzato
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + Hepzato
|
DC5HU3V
|
Hepzato
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vemurafenib + Ixabepilone
|
DC8KDOL
|
Ixabepilone
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vemurafenib + Ixabepilone
|
DC6ORC6
|
Ixabepilone
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Vemurafenib + Ixabepilone
|
DCQH8UY
|
Ixabepilone
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Vemurafenib + Ixabepilone
|
DCAWUXX
|
Ixabepilone
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Vemurafenib + Ixabepilone
|
DCYIIA1
|
Ixabepilone
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Vemurafenib + Ixabepilone
|
DCZ1CO3
|
Ixabepilone
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Ixabepilone
|
DC6ANF6
|
Ixabepilone
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Vemurafenib + Ixabepilone
|
DCBUPXP
|
Ixabepilone
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Vemurafenib + Ixabepilone
|
DC0CSKK
|
Ixabepilone
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Vemurafenib + Ixabepilone
|
DCDAF15
|
Ixabepilone
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Ixabepilone
|
DC970SC
|
Ixabepilone
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DC06LVW
|
Dactinomycin
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCTSATO
|
Dactinomycin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCPJ0XN
|
Dactinomycin
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCJYKYD
|
Dactinomycin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCU71LX
|
Dactinomycin
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCZIV2U
|
Dactinomycin
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DC1759N
|
Dactinomycin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DC0JR1W
|
Dactinomycin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCBVANE
|
Dactinomycin
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DC6PGIV
|
Dactinomycin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCD2XPX
|
Dactinomycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DC9N6KJ
|
Dactinomycin
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCRX5AE
|
Dactinomycin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DC418ZG
|
Dactinomycin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCZEUS1
|
Dactinomycin
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCZYNAD
|
Dactinomycin
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCH0Q6L
|
Dactinomycin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCJ0OT5
|
Dactinomycin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCEIRZE
|
Dactinomycin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCGKDPT
|
Dactinomycin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DC4F423
|
Dactinomycin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCJUC4L
|
Dactinomycin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCS9E15
|
Dactinomycin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCHBIXH
|
Dactinomycin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCF32YH
|
Dactinomycin
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCDHD51
|
Dactinomycin
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DC8B8KR
|
Dactinomycin
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DC1QIQU
|
Dactinomycin
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCQBQHU
|
Dactinomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCN2VFE
|
Dactinomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DC8KH3Z
|
Dactinomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCD0K4Q
|
Dactinomycin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCMHSOQ
|
Dactinomycin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCY3LH0
|
Dactinomycin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCC8BIS
|
Dactinomycin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCKBA62
|
Dactinomycin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DC9XVRI
|
Dactinomycin
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCG6ZHM
|
Dactinomycin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCRGZD3
|
Dactinomycin
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCCVCA4
|
Dactinomycin
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCCDFJ8
|
Dactinomycin
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCHM46W
|
Dactinomycin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCVFE4B
|
Dactinomycin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DC15OQ6
|
Dactinomycin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCFUQ92
|
Dactinomycin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCOHQ47
|
Dactinomycin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCQGRQW
|
Dactinomycin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCE65UG
|
Dactinomycin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCY3WUG
|
Dactinomycin
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCRSXZV
|
Dactinomycin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Vemurafenib + Dactinomycin
|
DCJ24KS
|
Dactinomycin
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Vemurafenib + DFN-15
|
DCZURZ9
|
DFN-15
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Vemurafenib + DFN-15
|
DC5NRVU
|
DFN-15
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Vemurafenib + DFN-15
|
DCZV3S1
|
DFN-15
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Vemurafenib + DFN-15
|
DCXD3OD
|
DFN-15
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Vemurafenib + DFN-15
|
DCWVU15
|
DFN-15
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Vemurafenib + DFN-15
|
DCUOS6X
|
DFN-15
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vemurafenib + DFN-15
|
DCB6164
|
DFN-15
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + DFN-15
|
DCPNU21
|
DFN-15
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Vemurafenib + Lapatinib
|
DCK0GUN
|
Lapatinib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Lapatinib
|
DCMO8LK
|
Lapatinib
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Vemurafenib + Lapatinib
|
DCP3S4G
|
Lapatinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Vemurafenib + Lapatinib
|
DCBS3JP
|
Lapatinib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Vemurafenib + Lapatinib
|
DCK9QOB
|
Lapatinib
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + Lapatinib
|
DCGY1B4
|
Lapatinib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Vemurafenib + Lapatinib
|
DC3OUF7
|
Lapatinib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Vemurafenib + Lapatinib
|
DC6IFAS
|
Lapatinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Lapatinib
|
DCFUSYW
|
Lapatinib
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Vemurafenib + PMID28460551-Compound-2
|
DCR41EN
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vemurafenib + PMID28460551-Compound-2
|
DC68BFA
|
PMID28460551-Compound-2
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Vemurafenib + Crizotinib
|
DCGLZVK
|
Crizotinib
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Vemurafenib + Crizotinib
|
DCWMLWL
|
Crizotinib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + Crizotinib
|
DCG5RMP
|
Crizotinib
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Cyclophosphamide
|
DCQH5N5
|
Cyclophosphamide
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vemurafenib + LIAROZOLE
|
DC43B0S
|
LIAROZOLE
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + LIAROZOLE
|
DC1ZJQR
|
LIAROZOLE
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vemurafenib + LIAROZOLE
|
DC32KIC
|
LIAROZOLE
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + LIAROZOLE
|
DCPSUXA
|
LIAROZOLE
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Vemurafenib + LIAROZOLE
|
DCM6XQW
|
LIAROZOLE
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Vemurafenib + Methotrexate
|
DC3FRLD
|
Methotrexate
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vemurafenib + Vismodegib
|
DCLITKD
|
Vismodegib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Vemurafenib + Vismodegib
|
DCR9YMJ
|
Vismodegib
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Vemurafenib + Vismodegib
|
DCOHY1F
|
Vismodegib
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vemurafenib + Vismodegib
|
DC7RMY6
|
Vismodegib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Vemurafenib + Vismodegib
|
DC537BJ
|
Vismodegib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Vemurafenib + Vismodegib
|
DCBD8I4
|
Vismodegib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Vismodegib
|
DCEXVWL
|
Vismodegib
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Vemurafenib + Vismodegib
|
DCSVH93
|
Vismodegib
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Vemurafenib + Vismodegib
|
DC154PA
|
Vismodegib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Vemurafenib + Vismodegib
|
DCWQH8M
|
Vismodegib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Vemurafenib + Vismodegib
|
DCLRXWJ
|
Vismodegib
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vemurafenib + Vismodegib
|
DC9DZVO
|
Vismodegib
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + Vismodegib
|
DCAF0OM
|
Vismodegib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Vismodegib
|
DCXB58H
|
Vismodegib
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Vemurafenib + Isoniazid
|
DCSWD66
|
Isoniazid
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Vemurafenib + Isoniazid
|
DCYK8VN
|
Isoniazid
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Vemurafenib + Isoniazid
|
DCQ8L2Z
|
Isoniazid
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Vemurafenib + Isoniazid
|
DCYHZSK
|
Isoniazid
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Vemurafenib + Isoniazid
|
DCI4L74
|
Isoniazid
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Vemurafenib + Isoniazid
|
DCBPQ9F
|
Isoniazid
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Vemurafenib + Isoniazid
|
DCZZTRP
|
Isoniazid
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Vemurafenib + Isoniazid
|
DC07G84
|
Isoniazid
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Vemurafenib + Isoniazid
|
DC6HNLZ
|
Isoniazid
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + Isoniazid
|
DCP8TWE
|
Isoniazid
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vemurafenib + Isoniazid
|
DCQU80E
|
Isoniazid
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vemurafenib + Isoniazid
|
DCMRWDA
|
Isoniazid
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Vemurafenib + Isoniazid
|
DCDOKSM
|
Isoniazid
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Vemurafenib + Arsenic trioxide
|
DC5JA0F
|
Arsenic trioxide
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + Arsenic trioxide
|
DCUSIHG
|
Arsenic trioxide
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Vemurafenib + Arsenic trioxide
|
DCXMVW3
|
Arsenic trioxide
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Arsenic trioxide
|
DC5RF4H
|
Arsenic trioxide
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Vemurafenib + Arsenic trioxide
|
DC1PFT6
|
Arsenic trioxide
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Vemurafenib + Vemurafenib
|
DC9K490
|
Vemurafenib
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Vemurafenib + Vemurafenib
|
DC0M044
|
Vemurafenib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Vemurafenib + Vemurafenib
|
DCASCLM
|
Vemurafenib
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Vemurafenib + Vemurafenib
|
DCLO9BA
|
Vemurafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Vemurafenib + Vemurafenib
|
DC29V3V
|
Vemurafenib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Vemurafenib + Vemurafenib
|
DCN85WP
|
Vemurafenib
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + Vemurafenib
|
DCLV3TU
|
Vemurafenib
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Vemurafenib
|
DCEQ7CB
|
Vemurafenib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vemurafenib + Vemurafenib
|
DC6MVZI
|
Vemurafenib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Vemurafenib
|
DC5175T
|
Vemurafenib
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Vemurafenib + Lenalidomide
|
DC0R7EY
|
Lenalidomide
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Vemurafenib + Lenalidomide
|
DCGD34V
|
Lenalidomide
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCKNOV8
|
Plicamycin
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCWDJ7M
|
Plicamycin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCX4V28
|
Plicamycin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Vemurafenib + Plicamycin
|
DC38VHF
|
Plicamycin
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCNPD62
|
Plicamycin
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCQP8CV
|
Plicamycin
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Vemurafenib + Plicamycin
|
DC75NC1
|
Plicamycin
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Vemurafenib + Plicamycin
|
DC4HP4E
|
Plicamycin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Vemurafenib + Plicamycin
|
DC9IRHW
|
Plicamycin
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCPX94P
|
Plicamycin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCPOKL4
|
Plicamycin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
Vemurafenib + Plicamycin
|
DC6J564
|
Plicamycin
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Vemurafenib + Plicamycin
|
DC4QSK0
|
Plicamycin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCXI08Y
|
Plicamycin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCYV3QO
|
Plicamycin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCA533J
|
Plicamycin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCCMNUO
|
Plicamycin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCNYD2H
|
Plicamycin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCQT4Y1
|
Plicamycin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCAP0KL
|
Plicamycin
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCS7X3S
|
Plicamycin
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Vemurafenib + Plicamycin
|
DC15OV4
|
Plicamycin
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Vemurafenib + Plicamycin
|
DC011S5
|
Plicamycin
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCQ1ZBC
|
Plicamycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCKFN6S
|
Plicamycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCCYIUS
|
Plicamycin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCSKY2I
|
Plicamycin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCQ8Z73
|
Plicamycin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCM0TGK
|
Plicamycin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Vemurafenib + Plicamycin
|
DC9WWA4
|
Plicamycin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCQ0NHB
|
Plicamycin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCS9CG3
|
Plicamycin
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCVQHZW
|
Plicamycin
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vemurafenib + Plicamycin
|
DC82YZ1
|
Plicamycin
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCOO583
|
Plicamycin
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCRAZRU
|
Plicamycin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Vemurafenib + Plicamycin
|
DC1IN24
|
Plicamycin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCJAPNR
|
Plicamycin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCWG8IE
|
Plicamycin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCT1WMY
|
Plicamycin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCD3D9F
|
Plicamycin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCSTHBE
|
Plicamycin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCZEDLB
|
Plicamycin
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCSCYQT
|
Plicamycin
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Vemurafenib + Plicamycin
|
DCFAJ2B
|
Plicamycin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Vemurafenib + Nilotinib
|
DC66S7Q
|
Nilotinib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + Nilotinib
|
DC973SE
|
Nilotinib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Nilotinib
|
DCMXYYK
|
Nilotinib
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Vemurafenib + Nilotinib
|
DCQT8DI
|
Nilotinib
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Vemurafenib + Nilotinib
|
DCLP7BA
|
Nilotinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Vemurafenib + Nilotinib
|
DCBDZTW
|
Nilotinib
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Vemurafenib + Nilotinib
|
DCDOS0P
|
Nilotinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Vemurafenib + Nilotinib
|
DCGEHZ1
|
Nilotinib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Vemurafenib + Nilotinib
|
DCYEJHW
|
Nilotinib
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + Nilotinib
|
DCQ3NHP
|
Nilotinib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vemurafenib + Nilotinib
|
DCW6GLT
|
Nilotinib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Vemurafenib + Nilotinib
|
DC4WMD4
|
Nilotinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Nilotinib
|
DCIJWAR
|
Nilotinib
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Vemurafenib + Thioguanine
|
DCB2BQ4
|
Thioguanine
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Vemurafenib + Thioguanine
|
DCVCSDD
|
Thioguanine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Vemurafenib + Thioguanine
|
DCVJGOT
|
Thioguanine
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Vemurafenib + Thioguanine
|
DCLL0E6
|
Thioguanine
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Vemurafenib + Thioguanine
|
DC2WI1N
|
Thioguanine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Vemurafenib + Thioguanine
|
DC5FT5P
|
Thioguanine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + Thioguanine
|
DCPQ4N4
|
Thioguanine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Thioguanine
|
DCMCAMO
|
Thioguanine
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Vemurafenib + Thioguanine
|
DC5QA30
|
Thioguanine
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Vemurafenib + Thioguanine
|
DC8DZL7
|
Thioguanine
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Vemurafenib + Thioguanine
|
DCJ5CCN
|
Thioguanine
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Vemurafenib + Thioguanine
|
DCGF7QX
|
Thioguanine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Vemurafenib + Thioguanine
|
DC8T9WI
|
Thioguanine
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Vemurafenib + Thioguanine
|
DCVTBS0
|
Thioguanine
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Vemurafenib + Thioguanine
|
DCTYLNY
|
Thioguanine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + Thioguanine
|
DC2G8CE
|
Thioguanine
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Thioguanine
|
DCTIEM3
|
Thioguanine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vemurafenib + Thioguanine
|
DCSHACK
|
Thioguanine
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Vemurafenib + Thioguanine
|
DCKTI38
|
Thioguanine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Thioguanine
|
DCFRRS4
|
Thioguanine
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Vemurafenib + Triapine
|
DCGWQH0
|
Triapine
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Vemurafenib + Triapine
|
DC03RU3
|
Triapine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Vemurafenib + Triapine
|
DCWSQQK
|
Triapine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Vemurafenib + ABIRATERONE
|
DCAJTSY
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Vemurafenib + ABIRATERONE
|
DCV2PB9
|
ABIRATERONE
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Vemurafenib + ABIRATERONE
|
DC8I94F
|
ABIRATERONE
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Vemurafenib + ABIRATERONE
|
DCTYFNK
|
ABIRATERONE
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Vemurafenib + ABIRATERONE
|
DCYVLAV
|
ABIRATERONE
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Vemurafenib + ABIRATERONE
|
DCGVOWP
|
ABIRATERONE
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + ABIRATERONE
|
DCK3NJS
|
ABIRATERONE
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Vemurafenib + ABIRATERONE
|
DCO07YW
|
ABIRATERONE
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Vemurafenib + ABIRATERONE
|
DCENWUQ
|
ABIRATERONE
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Vemurafenib + ABIRATERONE
|
DCJV67P
|
ABIRATERONE
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vemurafenib + ABIRATERONE
|
DC8L4QU
|
ABIRATERONE
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + ABIRATERONE
|
DCUG9EQ
|
ABIRATERONE
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + ABIRATERONE
|
DCA6DAM
|
ABIRATERONE
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vemurafenib + ABIRATERONE
|
DCZSFXT
|
ABIRATERONE
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vemurafenib + 10-hydroxycamptothecin
|
DCU7Y52
|
10-hydroxycamptothecin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + 10-hydroxycamptothecin
|
DCCTHFD
|
10-hydroxycamptothecin
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vemurafenib + 10-hydroxycamptothecin
|
DCJH50E
|
10-hydroxycamptothecin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + 10-hydroxycamptothecin
|
DCJI54G
|
10-hydroxycamptothecin
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vemurafenib + Topetecan
|
DCSW6FS
|
Topetecan
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
Vemurafenib + Amonafide
|
DCI0LLP
|
Amonafide
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + Amonafide
|
DCAJXYV
|
Amonafide
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Amonafide
|
DCU6020
|
Amonafide
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Vemurafenib + Amonafide
|
DCSMEQH
|
Amonafide
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + Amonafide
|
DC3WVTI
|
Amonafide
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Amonafide
|
DCIBUAX
|
Amonafide
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vemurafenib + Pralatrexate
|
DC91KK3
|
Pralatrexate
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Vemurafenib + Pralatrexate
|
DCSOI0K
|
Pralatrexate
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Vemurafenib + Pralatrexate
|
DCQN6LK
|
Pralatrexate
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Vemurafenib + Pralatrexate
|
DC1RVM0
|
Pralatrexate
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Vemurafenib + Pralatrexate
|
DC8QUQ9
|
Pralatrexate
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Vemurafenib + Pralatrexate
|
DCXN20E
|
Pralatrexate
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Vemurafenib + Pralatrexate
|
DC5H598
|
Pralatrexate
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Vemurafenib + Pralatrexate
|
DCMTEEO
|
Pralatrexate
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Pralatrexate
|
DC2DVFT
|
Pralatrexate
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vemurafenib + Terameprocol
|
DCRQR3H
|
Terameprocol
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Vemurafenib + Terameprocol
|
DCLE032
|
Terameprocol
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Vemurafenib + Terameprocol
|
DCJEAXE
|
Terameprocol
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Vemurafenib + Terameprocol
|
DCWZDJQ
|
Terameprocol
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Vemurafenib + Terameprocol
|
DCXMIGI
|
Terameprocol
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Vemurafenib + Terameprocol
|
DCM9RZ0
|
Terameprocol
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Vemurafenib + Terameprocol
|
DCNXUP5
|
Terameprocol
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Vemurafenib + Terameprocol
|
DCZDZK9
|
Terameprocol
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Vemurafenib + Terameprocol
|
DCIU4WO
|
Terameprocol
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Vemurafenib + Terameprocol
|
DCXHJG4
|
Terameprocol
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Vemurafenib + Terameprocol
|
DC0UZ9T
|
Terameprocol
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Vemurafenib + Terameprocol
|
DCIZWUD
|
Terameprocol
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Vemurafenib + Terameprocol
|
DCQXBOS
|
Terameprocol
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Vemurafenib + Terameprocol
|
DCCANZU
|
Terameprocol
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Vemurafenib + Terameprocol
|
DCZO15L
|
Terameprocol
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Vemurafenib + Terameprocol
|
DC3GULW
|
Terameprocol
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + Terameprocol
|
DC5YRXJ
|
Terameprocol
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vemurafenib + Terameprocol
|
DCUZN1R
|
Terameprocol
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Vemurafenib + Terameprocol
|
DCRNDL8
|
Terameprocol
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Vemurafenib + SCH 727965
|
DCT012Z
|
SCH 727965
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Vemurafenib + SCH 727965
|
DCAP27Y
|
SCH 727965
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Vemurafenib + SCH 727965
|
DC6L973
|
SCH 727965
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Vemurafenib + SCH 727965
|
DC2K4HS
|
SCH 727965
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + SCH 727965
|
DCEMB2P
|
SCH 727965
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Vemurafenib + SCH 727965
|
DC71HE3
|
SCH 727965
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Vemurafenib + SCH 727965
|
DCYO5TT
|
SCH 727965
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Vemurafenib + SCH 727965
|
DC1A7LL
|
SCH 727965
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + SCH 727965
|
DCA3ZM0
|
SCH 727965
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + Ifosfamide
|
DCQNTXV
|
Ifosfamide
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Vemurafenib + Ifosfamide
|
DCYS3NL
|
Ifosfamide
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Vemurafenib + Ifosfamide
|
DCMBIZX
|
Ifosfamide
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vemurafenib + Ifosfamide
|
DCELYBC
|
Ifosfamide
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vemurafenib + Ifosfamide
|
DC8WZSH
|
Ifosfamide
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Dexrazoxane
|
DC9A563
|
Dexrazoxane
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Vemurafenib + Dexrazoxane
|
DCONYNU
|
Dexrazoxane
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Vemurafenib + Dexrazoxane
|
DC9JJL8
|
Dexrazoxane
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Vemurafenib + Dexrazoxane
|
DCL114G
|
Dexrazoxane
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Dexrazoxane
|
DC57H0M
|
Dexrazoxane
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Vemurafenib + Dexrazoxane
|
DC01N7V
|
Dexrazoxane
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Vemurafenib + Dexrazoxane
|
DCEDVQR
|
Dexrazoxane
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + Dexrazoxane
|
DCGVF3Z
|
Dexrazoxane
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Dexrazoxane
|
DC19SAM
|
Dexrazoxane
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vemurafenib + Docetaxel
|
DCGH6TV
|
Docetaxel
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vemurafenib + Docetaxel
|
DCJG8TE
|
Docetaxel
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
Vemurafenib + Docetaxel
|
DCLPGLM
|
Docetaxel
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
Vemurafenib + Docetaxel
|
DCYZA87
|
Docetaxel
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + Docetaxel
|
DC4O27L
|
Docetaxel
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vemurafenib + Docetaxel
|
DC1AQE5
|
Docetaxel
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + Docetaxel
|
DCXTZCI
|
Docetaxel
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Docetaxel
|
DCMNEM6
|
Docetaxel
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vemurafenib + Docetaxel
|
DC0OBFN
|
Docetaxel
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Vemurafenib + Docetaxel
|
DC2SQTT
|
Docetaxel
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Vemurafenib + Raloxifene
|
DCT21A4
|
Raloxifene
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Vemurafenib + Raloxifene
|
DCMEGOI
|
Raloxifene
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Vemurafenib + Raloxifene
|
DCSM29I
|
Raloxifene
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Vemurafenib + Raloxifene
|
DCU59AE
|
Raloxifene
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Vemurafenib + Raloxifene
|
DC37E6D
|
Raloxifene
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Vemurafenib + Raloxifene
|
DCP38FI
|
Raloxifene
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Vemurafenib + Raloxifene
|
DCS3DOS
|
Raloxifene
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Vemurafenib + Raloxifene
|
DCRR70K
|
Raloxifene
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Vemurafenib + Raloxifene
|
DCO73N6
|
Raloxifene
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Vemurafenib + Raloxifene
|
DCSVOSO
|
Raloxifene
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Vemurafenib + Raloxifene
|
DCOKXJM
|
Raloxifene
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Vemurafenib + Raloxifene
|
DCAPZ67
|
Raloxifene
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Vemurafenib + Raloxifene
|
DC9RZS7
|
Raloxifene
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Vemurafenib + Raloxifene
|
DC8FJB0
|
Raloxifene
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Vemurafenib + Raloxifene
|
DC5ERI8
|
Raloxifene
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Vemurafenib + Raloxifene
|
DCBJ5J9
|
Raloxifene
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Vemurafenib + Raloxifene
|
DC683PV
|
Raloxifene
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Vemurafenib + Raloxifene
|
DCI6IDY
|
Raloxifene
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + Raloxifene
|
DCUSHKP
|
Raloxifene
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + Raloxifene
|
DC9RYK0
|
Raloxifene
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Raloxifene
|
DC6GNXZ
|
Raloxifene
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vemurafenib + Raloxifene
|
DCGAX2H
|
Raloxifene
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Vemurafenib + Raloxifene
|
DC6JHES
|
Raloxifene
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vemurafenib + Raloxifene
|
DCY95VW
|
Raloxifene
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vemurafenib + Raloxifene
|
DC9QB02
|
Raloxifene
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Vemurafenib + Raloxifene
|
DCEAIH5
|
Raloxifene
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Raloxifene
|
DCA7WKK
|
Raloxifene
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Vemurafenib + Raloxifene
|
DC9SLJS
|
Raloxifene
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Vemurafenib + Raloxifene
|
DC1Z0UZ
|
Raloxifene
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Vemurafenib + Bendamustine hydrochloride
|
DC7GC4Y
|
Bendamustine hydrochloride
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Vemurafenib + Bendamustine hydrochloride
|
DC66MDC
|
Bendamustine hydrochloride
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vemurafenib + Bendamustine hydrochloride
|
DCBG4ID
|
Bendamustine hydrochloride
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Vemurafenib + Bendamustine hydrochloride
|
DC7ULW5
|
Bendamustine hydrochloride
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Vemurafenib + Bendamustine hydrochloride
|
DCZ7S1A
|
Bendamustine hydrochloride
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + Bendamustine hydrochloride
|
DCXU1JN
|
Bendamustine hydrochloride
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Bendamustine hydrochloride
|
DCX1M0V
|
Bendamustine hydrochloride
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Vemurafenib + Bendamustine hydrochloride
|
DCR3OTO
|
Bendamustine hydrochloride
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + Bendamustine hydrochloride
|
DCGXDYX
|
Bendamustine hydrochloride
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vemurafenib + Bendamustine hydrochloride
|
DCMLDX1
|
Bendamustine hydrochloride
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vemurafenib + Bendamustine hydrochloride
|
DCTA3VG
|
Bendamustine hydrochloride
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Vemurafenib + Bendamustine hydrochloride
|
DCHKEHV
|
Bendamustine hydrochloride
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Vemurafenib + Bendamustine hydrochloride
|
DCQPX0L
|
Bendamustine hydrochloride
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Vemurafenib + Trifluridine
|
DCSIKAE
|
Trifluridine
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Vemurafenib + Trifluridine
|
DCSIW82
|
Trifluridine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + Trifluridine
|
DC7E5LL
|
Trifluridine
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Vemurafenib + Trifluridine
|
DCW2AW3
|
Trifluridine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Trifluridine
|
DCO4E7Q
|
Trifluridine
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vemurafenib + Trifluridine
|
DC7XHXM
|
Trifluridine
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vemurafenib + Trifluridine
|
DCSOVD1
|
Trifluridine
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Sirolimus
|
DCI4L77
|
Sirolimus
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Vemurafenib + Sirolimus
|
DC9GAAC
|
Sirolimus
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Vemurafenib + Sirolimus
|
DCTACOE
|
Sirolimus
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
Vemurafenib + Sirolimus
|
DC15YFY
|
Sirolimus
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Vemurafenib + Sirolimus
|
DCB8G8P
|
Sirolimus
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + Sirolimus
|
DC23FJP
|
Sirolimus
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
Vemurafenib + Sirolimus
|
DCCQXLI
|
Sirolimus
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Vemurafenib + Sirolimus
|
DCM492V
|
Sirolimus
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Sirolimus
|
DCK6GE5
|
Sirolimus
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Vemurafenib + Sirolimus
|
DC3PF7Z
|
Sirolimus
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Vemurafenib + Sirolimus
|
DCC1N6T
|
Sirolimus
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + Sirolimus
|
DCNOFM3
|
Sirolimus
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vemurafenib + Sirolimus
|
DCOBAGD
|
Sirolimus
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Sirolimus
|
DC59RVX
|
Sirolimus
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Vemurafenib + Sirolimus
|
DCUK71T
|
Sirolimus
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Vemurafenib + Sirolimus
|
DCRMUNX
|
Sirolimus
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Vemurafenib + Sirolimus
|
DC8TNUI
|
Sirolimus
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Vemurafenib + Letrozole
|
DC6ZOQW
|
Letrozole
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Vemurafenib + Letrozole
|
DC9F4QF
|
Letrozole
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Vemurafenib + Letrozole
|
DC0X2RZ
|
Letrozole
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Vemurafenib + Letrozole
|
DC75W88
|
Letrozole
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Vemurafenib + Letrozole
|
DCNA32Y
|
Letrozole
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Vemurafenib + Letrozole
|
DCIVTHE
|
Letrozole
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Vemurafenib + Letrozole
|
DCVF3ZJ
|
Letrozole
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Vemurafenib + Letrozole
|
DCX3Y5O
|
Letrozole
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Vemurafenib + Letrozole
|
DCJ5S5U
|
Letrozole
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vemurafenib + Letrozole
|
DCV2FAF
|
Letrozole
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vemurafenib + Letrozole
|
DCM40Y4
|
Letrozole
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Letrozole
|
DC9Z977
|
Letrozole
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Vemurafenib + Letrozole
|
DC48YAO
|
Letrozole
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Vemurafenib + Letrozole
|
DC7MLZO
|
Letrozole
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Vemurafenib + Mitomycin
|
DCLQZXG
|
Mitomycin
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Vemurafenib + Mitomycin
|
DCXOTWU
|
Mitomycin
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Vemurafenib + Mitomycin
|
DCKKYRH
|
Mitomycin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Vemurafenib + Mitomycin
|
DCGLLZH
|
Mitomycin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Vemurafenib + Mitomycin
|
DC9T6FL
|
Mitomycin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + Mitomycin
|
DCD245X
|
Mitomycin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
Vemurafenib + Mitomycin
|
DCWQFVC
|
Mitomycin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Mitomycin
|
DCYAYUU
|
Mitomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Vemurafenib + Mitomycin
|
DC5MOAO
|
Mitomycin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Vemurafenib + Mitomycin
|
DC1J71B
|
Mitomycin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Vemurafenib + Mitomycin
|
DC3NV5J
|
Mitomycin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + Mitomycin
|
DCKBZ4P
|
Mitomycin
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vemurafenib + Mitomycin
|
DCOFPPI
|
Mitomycin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vemurafenib + Mitomycin
|
DCPIXIN
|
Mitomycin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vemurafenib + Mitomycin
|
DCZ1YTR
|
Mitomycin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Mitomycin
|
DCKZNOH
|
Mitomycin
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Vemurafenib + SY-1425
|
DCA0WQ6
|
SY-1425
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vemurafenib + SY-1425
|
DCN5NOW
|
SY-1425
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Vemurafenib + SY-1425
|
DC2MWY3
|
SY-1425
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
Vemurafenib + SY-1425
|
DCOY3XQ
|
SY-1425
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Vemurafenib + SY-1425
|
DCVKSKH
|
SY-1425
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Vemurafenib + SY-1425
|
DCHPZ1D
|
SY-1425
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vemurafenib + SY-1425
|
DCDACK7
|
SY-1425
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + SY-1425
|
DCC61HU
|
SY-1425
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + SY-1425
|
DCZ1ICY
|
SY-1425
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Vemurafenib + Uracil mustard
|
DCUH7HV
|
Uracil mustard
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vemurafenib + Uracil mustard
|
DCXJWF5
|
Uracil mustard
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
Vemurafenib + Uracil mustard
|
DC17ZFO
|
Uracil mustard
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Vemurafenib + Uracil mustard
|
DCDC4JX
|
Uracil mustard
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Vemurafenib + Uracil mustard
|
DC06JX4
|
Uracil mustard
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
Vemurafenib + Uracil mustard
|
DCR5GOS
|
Uracil mustard
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + Uracil mustard
|
DCL97SP
|
Uracil mustard
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Uracil mustard
|
DCZC3GG
|
Uracil mustard
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Vemurafenib + Uracil mustard
|
DCKRXJ2
|
Uracil mustard
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vemurafenib + Uracil mustard
|
DCE15QU
|
Uracil mustard
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + Uracil mustard
|
DC6YLPD
|
Uracil mustard
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + Uracil mustard
|
DCCJA8M
|
Uracil mustard
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Uracil mustard
|
DCA6H18
|
Uracil mustard
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vemurafenib + Uracil mustard
|
DCDXBUI
|
Uracil mustard
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Vemurafenib + Uracil mustard
|
DCFBDE9
|
Uracil mustard
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Vemurafenib + Vincristine
|
DC5UWF8
|
Vincristine
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Vemurafenib + Vincristine
|
DCRNMFJ
|
Vincristine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Vemurafenib + Vincristine
|
DC38M64
|
Vincristine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
Vemurafenib + Vincristine
|
DCI1N4J
|
Vincristine
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Vemurafenib + Vincristine
|
DCBKY6H
|
Vincristine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Vincristine
|
DCOAZB9
|
Vincristine
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Vemurafenib + Vincristine
|
DCG07QS
|
Vincristine
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Vincristine
|
DCL8Y3E
|
Vincristine
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Vemurafenib + Vincristine
|
DCT1W3L
|
Vincristine
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Vemurafenib + Arfolitixorin
|
DC2HB7K
|
Arfolitixorin
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Vemurafenib + Arfolitixorin
|
DCLA43W
|
Arfolitixorin
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Vemurafenib + Arfolitixorin
|
DCDGYDO
|
Arfolitixorin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Vemurafenib + Arfolitixorin
|
DCMENQZ
|
Arfolitixorin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + Arfolitixorin
|
DCR81DC
|
Arfolitixorin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Arfolitixorin
|
DCW18LO
|
Arfolitixorin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Vemurafenib + Arfolitixorin
|
DCOVCSJ
|
Arfolitixorin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + Arfolitixorin
|
DCMP9CA
|
Arfolitixorin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Arfolitixorin
|
DC1S73L
|
Arfolitixorin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Vemurafenib + BIO-300
|
DCIIZ2R
|
BIO-300
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vemurafenib + BIO-300
|
DCOKI2P
|
BIO-300
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Vemurafenib + BIO-300
|
DCFKYUC
|
BIO-300
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Vemurafenib + BIO-300
|
DCK10LF
|
BIO-300
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Vemurafenib + BIO-300
|
DCWWEU2
|
BIO-300
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + BIO-300
|
DCPYZC1
|
BIO-300
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
Vemurafenib + BIO-300
|
DC8S4R5
|
BIO-300
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Vemurafenib + BIO-300
|
DCY211K
|
BIO-300
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Vemurafenib + BIO-300
|
DCJL4GD
|
BIO-300
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Vemurafenib + BIO-300
|
DCO0U6R
|
BIO-300
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vemurafenib + BIO-300
|
DCE96GM
|
BIO-300
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + BIO-300
|
DCVFHJ2
|
BIO-300
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + BIO-300
|
DC129IN
|
BIO-300
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vemurafenib + BIO-300
|
DCQJLFT
|
BIO-300
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Vemurafenib + BIO-300
|
DCXSVR7
|
BIO-300
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Vemurafenib + BIO-300
|
DCT015L
|
BIO-300
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Vemurafenib + BIO-300
|
DCR6XPJ
|
BIO-300
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Vemurafenib + Altretamine
|
DC3AZUN
|
Altretamine
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + TEM
|
DCF32SD
|
TEM
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Vemurafenib + TEM
|
DC3QTEN
|
TEM
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Vemurafenib + TEM
|
DCYWUVZ
|
TEM
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + TEM
|
DCN4LMR
|
TEM
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Vemurafenib + TEM
|
DCEHE2P
|
TEM
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Vemurafenib + TEM
|
DCE0D6V
|
TEM
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Vemurafenib + TEM
|
DC1N1R7
|
TEM
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Vemurafenib + TEM
|
DCUKLVP
|
TEM
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Vemurafenib + TEM
|
DC3T3G5
|
TEM
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Vemurafenib + TEM
|
DCN2CQC
|
TEM
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + TEM
|
DCPE7K0
|
TEM
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Vemurafenib + TEM
|
DCJL033
|
TEM
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + TEM
|
DCO5CVJ
|
TEM
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Vemurafenib + JNK-IN-8
|
DC69IXT
|
JNK-IN-8
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Vemurafenib + JNK-IN-8
|
DCA97BY
|
JNK-IN-8
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + JNK-IN-8
|
DC8G7JL
|
JNK-IN-8
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vemurafenib + JNK-IN-8
|
DCVUFQ5
|
JNK-IN-8
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Vemurafenib + Idarubicin
|
DCKJGUB
|
Idarubicin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Vemurafenib + Idarubicin
|
DC5G4R1
|
Idarubicin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Vemurafenib + Idarubicin
|
DCMOAAC
|
Idarubicin
|
Glioblastoma? (Cell Line: T98G)
|
[3] |
|
Vemurafenib + Idarubicin
|
DCCUXPA
|
Idarubicin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DCGFYPI
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DCPFIWU
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DCLR6T2
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DC7CVQJ
|
Indazole derivative 5
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DC4Z0RZ
|
Indazole derivative 5
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DCA5Z2U
|
Indazole derivative 5
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DC4GPVI
|
Indazole derivative 5
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DCCPTFX
|
Indazole derivative 5
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DC4HKRM
|
Indazole derivative 5
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DC9A2DD
|
Indazole derivative 5
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DCEKSSN
|
Indazole derivative 5
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DCJPST8
|
Indazole derivative 5
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DCCXKGE
|
Indazole derivative 5
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DC40TN1
|
Indazole derivative 5
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DC83W8L
|
Indazole derivative 5
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DCF13QT
|
Indazole derivative 5
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DC4V7SD
|
Indazole derivative 5
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DC3W0W3
|
Indazole derivative 5
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DCE2FD8
|
Indazole derivative 5
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Vemurafenib + Imatinib
|
DCG9OM7
|
Imatinib
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Vemurafenib + Imatinib
|
DCUHGY8
|
Imatinib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Imatinib
|
DC33FIN
|
Imatinib
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Vemurafenib + Imatinib
|
DCULXHR
|
Imatinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Vemurafenib + Imatinib
|
DCV2M2A
|
Imatinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Vemurafenib + Imatinib
|
DCZS8YW
|
Imatinib
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Vemurafenib + Bleomycin
|
DCXJYOJ
|
Bleomycin
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vemurafenib + Bleomycin
|
DCTX8I9
|
Bleomycin
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Vemurafenib + Bleomycin
|
DCG9FEZ
|
Bleomycin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
Vemurafenib + Bleomycin
|
DCJCMNN
|
Bleomycin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + Bleomycin
|
DCB9TIJ
|
Bleomycin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Bleomycin
|
DCFXYDM
|
Bleomycin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Vemurafenib + Bleomycin
|
DCGJXCB
|
Bleomycin
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Vemurafenib + Bleomycin
|
DCLZWWP
|
Bleomycin
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Vemurafenib + Bleomycin
|
DCGVNST
|
Bleomycin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Vemurafenib + Bleomycin
|
DCXPCF2
|
Bleomycin
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vemurafenib + Bleomycin
|
DCA6P5H
|
Bleomycin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + Bleomycin
|
DCBKHWY
|
Bleomycin
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Bortezomib
|
DC37G36
|
Bortezomib
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vemurafenib + Bortezomib
|
DCDKMLJ
|
Bortezomib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Vemurafenib + Bortezomib
|
DC1V05R
|
Bortezomib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
Vemurafenib + Bortezomib
|
DCB13M2
|
Bortezomib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Vemurafenib + Bortezomib
|
DCRSKA7
|
Bortezomib
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Vemurafenib + Bortezomib
|
DCXOPIA
|
Bortezomib
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vemurafenib + Bortezomib
|
DC2C8W6
|
Bortezomib
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vemurafenib + Anastrozole
|
DC6BIYS
|
Anastrozole
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Vemurafenib + Anastrozole
|
DCI51X2
|
Anastrozole
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Vemurafenib + Anastrozole
|
DCTB00B
|
Anastrozole
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Anastrozole
|
DCD00EV
|
Anastrozole
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Vemurafenib + Anastrozole
|
DCJXIE1
|
Anastrozole
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Vemurafenib + Anastrozole
|
DCDOCGY
|
Anastrozole
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vemurafenib + Anastrozole
|
DCJ146O
|
Anastrozole
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Vemurafenib + Dacarbazine
|
DC1IWZQ
|
Dacarbazine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Vemurafenib + Dacarbazine
|
DCUS1SA
|
Dacarbazine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Vemurafenib + Dacarbazine
|
DC05QQO
|
Dacarbazine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Vemurafenib + Dacarbazine
|
DCCCS63
|
Dacarbazine
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Vemurafenib + Dacarbazine
|
DC36LWS
|
Dacarbazine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Vemurafenib + Dacarbazine
|
DCOUX7J
|
Dacarbazine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + Dacarbazine
|
DC2VNAL
|
Dacarbazine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Dacarbazine
|
DC9LLTD
|
Dacarbazine
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Vemurafenib + Dacarbazine
|
DCGURRG
|
Dacarbazine
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Vemurafenib + Dacarbazine
|
DCBNDYL
|
Dacarbazine
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Vemurafenib + Dacarbazine
|
DCHO2UV
|
Dacarbazine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Vemurafenib + Dacarbazine
|
DC1VBZM
|
Dacarbazine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Vemurafenib + Dacarbazine
|
DCTJ919
|
Dacarbazine
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vemurafenib + Dacarbazine
|
DC3A3M2
|
Dacarbazine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + Dacarbazine
|
DCLKA7T
|
Dacarbazine
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Dacarbazine
|
DCTWX7M
|
Dacarbazine
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + Dacarbazine
|
DCQLPX0
|
Dacarbazine
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vemurafenib + Dacarbazine
|
DCOW5VF
|
Dacarbazine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vemurafenib + Dacarbazine
|
DCR8L8N
|
Dacarbazine
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Vemurafenib + Dacarbazine
|
DCWAQTC
|
Dacarbazine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Valrubicin
|
DC58HRN
|
Valrubicin
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vemurafenib + Valrubicin
|
DC38X64
|
Valrubicin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Vemurafenib + Valrubicin
|
DCMQFCW
|
Valrubicin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Vemurafenib + Valrubicin
|
DCHKPDP
|
Valrubicin
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Vemurafenib + Valrubicin
|
DCB5B60
|
Valrubicin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
Vemurafenib + Valrubicin
|
DCCOGH2
|
Valrubicin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Vemurafenib + Valrubicin
|
DCTZ2YQ
|
Valrubicin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
Vemurafenib + Valrubicin
|
DCTU84S
|
Valrubicin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Vemurafenib + Valrubicin
|
DC7I4O5
|
Valrubicin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Valrubicin
|
DC29OJS
|
Valrubicin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Vemurafenib + Valrubicin
|
DCE42W4
|
Valrubicin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Vemurafenib + Valrubicin
|
DC5QEY2
|
Valrubicin
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Vemurafenib + Valrubicin
|
DCTINME
|
Valrubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Vemurafenib + Valrubicin
|
DCNUTPF
|
Valrubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Vemurafenib + Valrubicin
|
DCKP6B0
|
Valrubicin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Vemurafenib + Valrubicin
|
DCHVQU8
|
Valrubicin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + Valrubicin
|
DC1XRDQ
|
Valrubicin
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vemurafenib + Valrubicin
|
DCN80NH
|
Valrubicin
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Valrubicin
|
DC8KN7T
|
Valrubicin
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + Valrubicin
|
DCB1US3
|
Valrubicin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vemurafenib + Valrubicin
|
DCR8A84
|
Valrubicin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Vemurafenib + Valrubicin
|
DCSXUYR
|
Valrubicin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Valrubicin
|
DCJ45H4
|
Valrubicin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Vemurafenib + Valrubicin
|
DCSUUFW
|
Valrubicin
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Vemurafenib + Topotecan
|
DC2PPXA
|
Topotecan
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Vemurafenib + Topotecan
|
DCL88PK
|
Topotecan
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Vemurafenib + Topotecan
|
DCQ8G3T
|
Topotecan
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Topotecan
|
DCWOCOK
|
Topotecan
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Vemurafenib + Topotecan
|
DCDAQG5
|
Topotecan
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vemurafenib + Topotecan
|
DCBMHRS
|
Topotecan
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Topotecan
|
DCB91CN
|
Topotecan
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Vemurafenib + Topotecan
|
DCTOU8B
|
Topotecan
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Vemurafenib + Topotecan
|
DCD4K9X
|
Topotecan
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Vemurafenib + Topotecan
|
DCIULU8
|
Topotecan
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Vemurafenib + Cabazitaxel
|
DCYX3ND
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vemurafenib + Cabazitaxel
|
DCONBC5
|
Cabazitaxel
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Vemurafenib + Cabazitaxel
|
DCZ4BW0
|
Cabazitaxel
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Vemurafenib + Cabazitaxel
|
DCB0MS8
|
Cabazitaxel
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Vemurafenib + Cabazitaxel
|
DC8LDBT
|
Cabazitaxel
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Vemurafenib + Cabazitaxel
|
DCRTOVS
|
Cabazitaxel
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Cabazitaxel
|
DC48UHP
|
Cabazitaxel
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Vemurafenib + Cabazitaxel
|
DCHW3PZ
|
Cabazitaxel
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Vemurafenib + Cabazitaxel
|
DCTC6C1
|
Cabazitaxel
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vemurafenib + Cabazitaxel
|
DCI7XQ5
|
Cabazitaxel
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Cabazitaxel
|
DCKRTC0
|
Cabazitaxel
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Vemurafenib + Cabazitaxel
|
DCUB5TH
|
Cabazitaxel
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Vemurafenib + Cabazitaxel
|
DCFNBPG
|
Cabazitaxel
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Vemurafenib + Cabazitaxel
|
DCHPWHI
|
Cabazitaxel
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Vemurafenib + Epirubicin
|
DCYHRRL
|
Epirubicin
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Vemurafenib + Epirubicin
|
DCD3UUG
|
Epirubicin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Vemurafenib + Epirubicin
|
DC6PDQ1
|
Epirubicin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Vemurafenib + Epirubicin
|
DCVMAQO
|
Epirubicin
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Vemurafenib + Epirubicin
|
DC8JDUS
|
Epirubicin
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Vemurafenib + Epirubicin
|
DCKEGKZ
|
Epirubicin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Vemurafenib + Epirubicin
|
DCAFV6K
|
Epirubicin
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Vemurafenib + Epirubicin
|
DC7SNBR
|
Epirubicin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Vemurafenib + Epirubicin
|
DCA8BQF
|
Epirubicin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Vemurafenib + Epirubicin
|
DCIUQEC
|
Epirubicin
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Vemurafenib + Epirubicin
|
DCEXFZK
|
Epirubicin
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Vemurafenib + Epirubicin
|
DCZ145J
|
Epirubicin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Vemurafenib + Epirubicin
|
DCHHSHW
|
Epirubicin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Vemurafenib + Epirubicin
|
DCYJTYD
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + Epirubicin
|
DCIXJZ2
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Epirubicin
|
DCXU1CI
|
Epirubicin
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Vemurafenib + Epirubicin
|
DCMOTMH
|
Epirubicin
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Vemurafenib + Epirubicin
|
DCR2YYE
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Vemurafenib + Epirubicin
|
DCMC9C8
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Vemurafenib + Epirubicin
|
DC6X8TI
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Vemurafenib + Epirubicin
|
DC7VHXT
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Vemurafenib + Epirubicin
|
DCCS9KD
|
Epirubicin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Vemurafenib + Epirubicin
|
DC77I6D
|
Epirubicin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Vemurafenib + Epirubicin
|
DC13R21
|
Epirubicin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Vemurafenib + Epirubicin
|
DCEBSQJ
|
Epirubicin
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + Epirubicin
|
DCV84ER
|
Epirubicin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Vemurafenib + Epirubicin
|
DCYC6FW
|
Epirubicin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vemurafenib + Epirubicin
|
DCK3R4I
|
Epirubicin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vemurafenib + Epirubicin
|
DCKORDW
|
Epirubicin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Vemurafenib + Epirubicin
|
DC939ZS
|
Epirubicin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Epirubicin
|
DCSOMCH
|
Epirubicin
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Vemurafenib + Epirubicin
|
DCA82QP
|
Epirubicin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Vemurafenib + Cisplatin
|
DCCPS8A
|
Cisplatin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Vemurafenib + Cisplatin
|
DC2AL07
|
Cisplatin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Vemurafenib + Cisplatin
|
DCV5I59
|
Cisplatin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Vemurafenib + Cisplatin
|
DCDW36K
|
Cisplatin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Vemurafenib + Cisplatin
|
DC8YIVU
|
Cisplatin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Vemurafenib + Vandetanib
|
DCD6FFS
|
Vandetanib
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vemurafenib + Vandetanib
|
DCYIFTC
|
Vandetanib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Vemurafenib + Vandetanib
|
DCJ3BCN
|
Vandetanib
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Vemurafenib + Vandetanib
|
DCLSUE4
|
Vandetanib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Vemurafenib + Vandetanib
|
DCY53QY
|
Vandetanib
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Vandetanib
|
DCDJOXP
|
Vandetanib
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + Chlorambucil
|
DCXTBXS
|
Chlorambucil
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Vemurafenib + Chlorambucil
|
DCBIXMG
|
Chlorambucil
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
Vemurafenib + Chlorambucil
|
DCWJIMM
|
Chlorambucil
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + Chlorambucil
|
DCHUYJ0
|
Chlorambucil
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Vemurafenib + Chlorambucil
|
DCGT4W1
|
Chlorambucil
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vemurafenib + Chlorambucil
|
DCF0X1E
|
Chlorambucil
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Sorafenib
|
DCOKFP0
|
Sorafenib
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + ER819762
|
DCAES0Z
|
ER819762
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Vemurafenib + ER819762
|
DCHWMU1
|
ER819762
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vemurafenib + ER819762
|
DCSSP5N
|
ER819762
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Vemurafenib + Azacitidine
|
DCF9F90
|
Azacitidine
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vemurafenib + Azacitidine
|
DCZIW8I
|
Azacitidine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + Azacitidine
|
DC7UIIZ
|
Azacitidine
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Vemurafenib + Azacitidine
|
DC8NA4Y
|
Azacitidine
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vemurafenib + Azacitidine
|
DCW1SDN
|
Azacitidine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vemurafenib + Azacitidine
|
DC6DU99
|
Azacitidine
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Vemurafenib + Pomalidomide
|
DCG73CU
|
Pomalidomide
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Vemurafenib + Pomalidomide
|
DC3XDZ7
|
Pomalidomide
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Vemurafenib + Pomalidomide
|
DCTMQ91
|
Pomalidomide
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Vemurafenib + Pomalidomide
|
DCWVDGI
|
Pomalidomide
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Vemurafenib + Pomalidomide
|
DCXRMWK
|
Pomalidomide
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Vemurafenib + Pomalidomide
|
DCB3R6H
|
Pomalidomide
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Vemurafenib + Pomalidomide
|
DC3BOXK
|
Pomalidomide
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Vemurafenib + Pomalidomide
|
DCIXGNL
|
Pomalidomide
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Vemurafenib + Pomalidomide
|
DCRP6LU
|
Pomalidomide
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Vemurafenib + Pomalidomide
|
DCU22AG
|
Pomalidomide
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + Pomalidomide
|
DCTD85S
|
Pomalidomide
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Vemurafenib + Pomalidomide
|
DC1YQQI
|
Pomalidomide
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Vemurafenib + Pomalidomide
|
DC8VCNR
|
Pomalidomide
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Vemurafenib + Pomalidomide
|
DCE64Q2
|
Pomalidomide
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Vemurafenib + Pomalidomide
|
DCE8GQX
|
Pomalidomide
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Vemurafenib + Pomalidomide
|
DCDWLTZ
|
Pomalidomide
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Vemurafenib + Pomalidomide
|
DCX7V7X
|
Pomalidomide
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Vemurafenib + Pomalidomide
|
DCGFLBX
|
Pomalidomide
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Vemurafenib + Pomalidomide
|
DCNC9XE
|
Pomalidomide
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Vemurafenib + Pomalidomide
|
DCSDY3C
|
Pomalidomide
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + Pomalidomide
|
DCRMPQF
|
Pomalidomide
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Vemurafenib + Pomalidomide
|
DC1BPA8
|
Pomalidomide
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vemurafenib + Pomalidomide
|
DC4H6K9
|
Pomalidomide
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vemurafenib + Pomalidomide
|
DC2G4KX
|
Pomalidomide
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Vemurafenib + Vinflunine
|
DCX2Y5S
|
Vinflunine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Vemurafenib + Vinflunine
|
DC1TOTN
|
Vinflunine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Vemurafenib + Vinflunine
|
DCF9QN6
|
Vinflunine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
Vemurafenib + Vinflunine
|
DC7C2HB
|
Vinflunine
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Vemurafenib + Vinflunine
|
DCDI7NC
|
Vinflunine
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
Vemurafenib + Vinflunine
|
DCM0MMJ
|
Vinflunine
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Vemurafenib + Vinflunine
|
DC7XLUY
|
Vinflunine
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Vemurafenib + Vinflunine
|
DCYXPH7
|
Vinflunine
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Vemurafenib + Vinflunine
|
DC2A6E2
|
Vinflunine
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vemurafenib + Vinflunine
|
DC0KTCJ
|
Vinflunine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + Vinflunine
|
DCBIUDG
|
Vinflunine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Vinflunine
|
DC76O3L
|
Vinflunine
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Vemurafenib + Mercaptopurine
|
DCDXEZB
|
Mercaptopurine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
Vemurafenib + Mercaptopurine
|
DCFLPWD
|
Mercaptopurine
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Vemurafenib + Mercaptopurine
|
DCR5Y1F
|
Mercaptopurine
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vemurafenib + Mercaptopurine
|
DCHLJYT
|
Mercaptopurine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + Mercaptopurine
|
DCDEKE4
|
Mercaptopurine
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Vemurafenib + Mercaptopurine
|
DC7QOZ8
|
Mercaptopurine
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Vemurafenib + Mepacrine
|
DC9FGQA
|
Mepacrine
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Vemurafenib + Mepacrine
|
DC9WRW5
|
Mepacrine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Vemurafenib + Mepacrine
|
DCQ92SN
|
Mepacrine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Vemurafenib + Mepacrine
|
DC1O6RS
|
Mepacrine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Vemurafenib + Mepacrine
|
DCQRECU
|
Mepacrine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + Taxol
|
DCD1XIQ
|
Taxol
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vemurafenib + Taxol
|
DCO6T85
|
Taxol
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Vemurafenib + Taxol
|
DCNGRG9
|
Taxol
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Vemurafenib + Taxol
|
DCUVWMK
|
Taxol
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
Vemurafenib + Taxol
|
DCKKJOY
|
Taxol
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + Taxol
|
DCCTRHC
|
Taxol
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Taxol
|
DC50C7F
|
Taxol
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Vemurafenib + Taxol
|
DCP1H2W
|
Taxol
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Vemurafenib + Taxol
|
DCGJ525
|
Taxol
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Vemurafenib + Taxol
|
DC29LNF
|
Taxol
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vemurafenib + Taxol
|
DCQHXP7
|
Taxol
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + Taxol
|
DC38X4Y
|
Taxol
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Taxol
|
DCACTSF
|
Taxol
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Vemurafenib + Fludarabine
|
DC53FMX
|
Fludarabine
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vemurafenib + Fludarabine
|
DCCD25Z
|
Fludarabine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + PMID28870136-Compound-43
|
DCYTC3X
|
PMID28870136-Compound-43
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Vemurafenib + PMID28870136-Compound-43
|
DCYYQIP
|
PMID28870136-Compound-43
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Vemurafenib + PMID28870136-Compound-43
|
DCXLNHD
|
PMID28870136-Compound-43
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Vemurafenib + PMID28870136-Compound-43
|
DCIV6X2
|
PMID28870136-Compound-43
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Vemurafenib + PMID28870136-Compound-43
|
DCHR1M5
|
PMID28870136-Compound-43
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + PMID28870136-Compound-43
|
DCY5CM4
|
PMID28870136-Compound-43
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Vemurafenib + PMID28870136-Compound-43
|
DCUIFWB
|
PMID28870136-Compound-43
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Vemurafenib + PMID28870136-Compound-43
|
DC5M9UJ
|
PMID28870136-Compound-43
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vemurafenib + PMID28870136-Compound-43
|
DC9ZH9P
|
PMID28870136-Compound-43
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + PMID28870136-Compound-43
|
DC2MY3F
|
PMID28870136-Compound-43
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + PMID28870136-Compound-43
|
DC5BL7I
|
PMID28870136-Compound-43
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Vemurafenib + PMID28870136-Compound-43
|
DCFFWPH
|
PMID28870136-Compound-43
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vemurafenib + PMID28870136-Compound-43
|
DCQL2TS
|
PMID28870136-Compound-43
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Vemurafenib + PMID28870136-Compound-43
|
DCJSNKM
|
PMID28870136-Compound-43
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Vemurafenib + FORMESTANE
|
DCR1JOD
|
FORMESTANE
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Vemurafenib + FORMESTANE
|
DCVG1M7
|
FORMESTANE
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Vemurafenib + FORMESTANE
|
DCMGL39
|
FORMESTANE
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vemurafenib + FORMESTANE
|
DCZG6HB
|
FORMESTANE
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Vemurafenib + FORMESTANE
|
DCEBDNR
|
FORMESTANE
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Vemurafenib + FORMESTANE
|
DCAFHRG
|
FORMESTANE
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Vemurafenib + FORMESTANE
|
DC2IBNR
|
FORMESTANE
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Vemurafenib + FORMESTANE
|
DCR1QG2
|
FORMESTANE
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Vemurafenib + FORMESTANE
|
DCMJLME
|
FORMESTANE
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Vemurafenib + FORMESTANE
|
DCCF4WH
|
FORMESTANE
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vemurafenib + FORMESTANE
|
DCMJ4R1
|
FORMESTANE
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vemurafenib + FORMESTANE
|
DCD8VWQ
|
FORMESTANE
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + FORMESTANE
|
DCDR3JE
|
FORMESTANE
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Vemurafenib + Aminolevulinic Acid Hydrochloride
|
DCEA14E
|
Aminolevulinic Acid Hydrochloride
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + Aminolevulinic Acid Hydrochloride
|
DCXVL55
|
Aminolevulinic Acid Hydrochloride
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vemurafenib + Aminolevulinic Acid Hydrochloride
|
DC8P9EB
|
Aminolevulinic Acid Hydrochloride
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + Estramustine
|
DC0PPCF
|
Estramustine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Vemurafenib + Estramustine
|
DC6IFFO
|
Estramustine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
Vemurafenib + Estramustine
|
DCWGRM6
|
Estramustine
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Vemurafenib + Estramustine
|
DCEAB6Y
|
Estramustine
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
Vemurafenib + Estramustine
|
DCF086C
|
Estramustine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + Estramustine
|
DC8AJB0
|
Estramustine
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Vemurafenib + Estramustine
|
DCX63PE
|
Estramustine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Vemurafenib + Estramustine
|
DC1ONYY
|
Estramustine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Vemurafenib + Estramustine
|
DC4PPHQ
|
Estramustine
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Estramustine
|
DCEYPOR
|
Estramustine
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Vemurafenib + Digitoxin
|
DC6B93R
|
Digitoxin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Vemurafenib + Digitoxin
|
DC81K2X
|
Digitoxin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Vemurafenib + Digitoxin
|
DCNSU76
|
Digitoxin
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Digitoxin
|
DCLBAMM
|
Digitoxin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Busulfan
|
DC67E76
|
Busulfan
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Vemurafenib + Busulfan
|
DCIXRZ4
|
Busulfan
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + Busulfan
|
DCLYQ4F
|
Busulfan
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + Dasatinib
|
DC3R18O
|
Dasatinib
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vemurafenib + Dasatinib
|
DC0X46Y
|
Dasatinib
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Vemurafenib + Dasatinib
|
DC6U4PB
|
Dasatinib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Vemurafenib + Dasatinib
|
DCYNB8X
|
Dasatinib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Dasatinib
|
DCBYW7P
|
Dasatinib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Vemurafenib + Dasatinib
|
DCG5R3Y
|
Dasatinib
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Vemurafenib + Dasatinib
|
DCPRQRW
|
Dasatinib
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Vemurafenib + Dasatinib
|
DCVHDG9
|
Dasatinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Vemurafenib + Dasatinib
|
DC3OSEM
|
Dasatinib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Vemurafenib + Dasatinib
|
DCCLNZH
|
Dasatinib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + Dasatinib
|
DCSR88L
|
Dasatinib
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Dasatinib
|
DC3K01L
|
Dasatinib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Vemurafenib + Dasatinib
|
DC4LVPG
|
Dasatinib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vemurafenib + Dasatinib
|
DC78VIG
|
Dasatinib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Vemurafenib + Dasatinib
|
DC6DP2F
|
Dasatinib
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Vemurafenib + Dasatinib
|
DCVX7IQ
|
Dasatinib
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Vismodegib + Vemurafenib
|
DC2GJ6A
|
Vismodegib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vismodegib + Vemurafenib
|
DC41F3Z
|
Vismodegib
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Vismodegib + Vemurafenib
|
DCC7ST3
|
Vismodegib
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vismodegib + Vemurafenib
|
DCQQMZK
|
Vismodegib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Vismodegib + Vemurafenib
|
DCALHKX
|
Vismodegib
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Vismodegib + Vemurafenib
|
DCT9NHR
|
Vismodegib
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Vismodegib + Vemurafenib
|
DCBVTVZ
|
Vismodegib
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Vismodegib + Vemurafenib
|
DC941DD
|
Vismodegib
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vismodegib + Vemurafenib
|
DCVMMZV
|
Vismodegib
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vismodegib + Vemurafenib
|
DCGFVBM
|
Vismodegib
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vismodegib + Vemurafenib
|
DCKAR38
|
Vismodegib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
| ------------------------------------------------------------------------------------ |
|
|
|
|
